RAPT Therapeutics, Inc. (NASDAQ:RAPT) Receives Consensus Recommendation of “Moderate Buy” from Analysts

RAPT Therapeutics, Inc. (NASDAQ:RAPT) has been assigned an average recommendation of “Moderate Buy” from the twelve analysts that are presently covering the stock, Marketbeat reports. Six investment analysts have rated the stock with a hold recommendation and six have assigned a buy recommendation to the company. The average 12 month target price among brokerages that have updated their coverage on the stock in the last year is $25.67.

Several research analysts have recently commented on the company. Leerink Partnrs lowered RAPT Therapeutics from an “outperform” rating to a “market perform” rating in a research report on Wednesday, February 21st. Barclays dropped their price target on shares of RAPT Therapeutics from $35.00 to $13.00 and set an “overweight” rating on the stock in a research report on Wednesday, February 21st. SVB Leerink lowered RAPT Therapeutics from an “outperform” rating to a “market perform” rating and reduced their price objective for the stock from $42.00 to $10.00 in a research note on Wednesday, February 21st. UBS Group downgraded shares of RAPT Therapeutics from a “buy” rating to a “neutral” rating and dropped their target price for the stock from $61.00 to $10.00 in a research report on Thursday, February 22nd. Finally, Wolfe Research initiated coverage on RAPT Therapeutics in a research report on Thursday, February 15th. They set an “outperform” rating and a $39.00 price target on the stock.

Hedge Funds Weigh In On RAPT Therapeutics

A number of large investors have recently modified their holdings of RAPT. China Universal Asset Management Co. Ltd. increased its holdings in shares of RAPT Therapeutics by 65.8% in the first quarter. China Universal Asset Management Co. Ltd. now owns 6,602 shares of the company’s stock valued at $59,000 after purchasing an additional 2,621 shares during the last quarter. Denali Advisors LLC acquired a new position in shares of RAPT Therapeutics in the first quarter valued at approximately $293,000. Los Angeles Capital Management LLC grew its stake in shares of RAPT Therapeutics by 442.7% in the first quarter. Los Angeles Capital Management LLC now owns 50,894 shares of the company’s stock worth $457,000 after purchasing an additional 41,516 shares during the last quarter. Kingdon Capital Management L.L.C. boosted its holdings in RAPT Therapeutics by 19.9% in the fourth quarter. Kingdon Capital Management L.L.C. now owns 965,828 shares of the company’s stock valued at $24,001,000 after acquiring an additional 160,000 shares during the last quarter. Finally, Perceptive Advisors LLC boosted its position in RAPT Therapeutics by 11.4% during the fourth quarter. Perceptive Advisors LLC now owns 2,139,950 shares of the company’s stock valued at $53,178,000 after acquiring an additional 219,292 shares during the last quarter. 99.09% of the stock is currently owned by institutional investors and hedge funds.

RAPT Therapeutics Stock Up 2.5 %

RAPT opened at $8.33 on Monday. RAPT Therapeutics has a 52-week low of $6.86 and a 52-week high of $27.35. The company has a 50 day moving average of $8.46 and a two-hundred day moving average of $15.36. The company has a market cap of $289.88 million, a P/E ratio of -2.74 and a beta of 0.52.

RAPT Therapeutics (NASDAQ:RAPT) last announced its earnings results on Thursday, March 7th. The company reported ($0.80) EPS for the quarter, beating the consensus estimate of ($0.85) by $0.05. Research analysts anticipate that RAPT Therapeutics will post -3.19 earnings per share for the current year.

About RAPT Therapeutics

RAPT Therapeutics, Inc, a clinical-stage immunology-based biopharmaceutical company, focuses on discovery, development, and commercialization of oral small molecule therapies for patients with unmet needs in oncology and inflammatory diseases in the United States. The company's lead inflammation drug candidate is zelnecirnon (RPT193), a C-C motif chemokine receptor 4 (CCR4) antagonist that selectively inhibit the migration of type 2 T helper cells into inflamed tissues.